Publication number: 20210353607
Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.
Type:
Application
Filed:
October 4, 2019
Publication date:
November 18, 2021
Applicants:
Sloan-Kettering Institute for Cancer Research, Tri-lnstitutional Therapeutics Discovery Institute, Inc.
Inventors:
Makoto Fushimi, Maurizio Scaltriti, Daniel Alan Heller, Carles Monterrubio Martinez, Amaia Arruabarrena Aristorena, Peter T. Meinke, Michael Andrew Foley, Yasutomi Asano, Kazuyoshi Aso, Hiroki Takahagi, Yosef Shamay, Jose Manuel Baselga Torres, Yusuke Sasaki, Mayako Michino